What advice does the DOJ have for pharma compliance teams?
The DOJ assistant attorney general emphasized proactive self-disclosure and hinted at how pharmaceuticals can best prepare for new trends in enforcement.
Personal devices in crisis? Risks vs. rewards of BYOD policies in pharmaceuticals
Pharmaceutical companies face a tough choice between enabling BYOD or issuing corporate devices. Understand the risks, rewards, and compliance factors of both.
